Overall survival of oropharyngeal cancer patients treated with different treatment modalities
| Autor: | József Barabás, Sándor Bogdán, Zsolt Németh, Mihály Vaszilkó, Norbert Velich, György Szabó, Krisztián Szigeti |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty medicine.medical_treatment Kaplan-Meier Estimate Internal medicine medicine Carcinoma Humans Stage (cooking) Survival rate Lymph node Aged Aged 80 and over Chemotherapy business.industry Proportional hazards model Age Factors Cancer Retrospective cohort study General Medicine Middle Aged medicine.disease Oropharyngeal Neoplasms medicine.anatomical_structure Otorhinolaryngology Regression Analysis Surgery Female business |
| Zdroj: | The Journal of craniofacial surgery. 18(1) |
| ISSN: | 1049-2275 |
| Popis: | Therapeutic modalities of use in tumor therapy can be applied in various combinations to treat malignant lesions of the mesopharynx. A study was made of the overall survival of patients with mesopharyngeal carcinoma treated with different modalities in our institution in the period 1995-2000. In this retrospective study, a total of 66 patients were divided into 4 groups: Patients who took part in 1) intra-arterial chemotherapy and subsequent irradiation; 2) intra-arterial chemotherapy and surgical care; 3) only surgical care; or 4) only irradiation or palliative treatment. In each group, the five-year survival rate was examined, as a function of the age of the patient, the initial tumor size, the lymph node status and the clinical stage. The five-year overall survival rate in group 1 was 28.57%, in both group 2 and group 3 was 66.66%, and in group 4 was 20%. For all of the 66 patients, it was 43.93%. For groups 2 and 3, the Kendall rank correction test did not reveal a significant effect of the lymph node state or the clinical stage on the survival, whereas the effects of the age and the initial tumor size did prove to be significant. The Cox regression test showed the latter of these two effects to be the stronger. As 64 of the 66 patients examined were treated for tumors in clinical stages III or IV, the five-year survival rate of 43.93% may be said to be good. The comparison of groups 2 and 3 revealed that (in spite of the poorer initial prognosis in group 2) the survival rates were the same, i.e. the neoadjuvant intra-arterial chemotherapy improved the prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|